Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study
Dermatology · 30.10.2024 · 1-9
DOI: 10.1159/000542275 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Dermatology, online erschienen am 30.10.2024. Verfasst von Jacob P Thyssen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Heterocyclic Compounds, 3-Ring, Dermatologic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Upadacitinib has demonstrated high and rapid rates of efficacy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) as assessed by the Eczema Area and Severity Index (EASI). This post hoc analysis assessed the EASI response in four anatomical regions for patients with moderate-to-severe AD treated with upadacitinib compared to dupilumab over 24 weeks.
Methods
Data from patients randomized 1:1 to receive upadacitinib 30 mg extended-release tablet orally once daily or dupilumab 300 mg by subcutaneous injection every 2 weeks after a loading dose of 600 mg in the Heads Up study were analyzed for achievement of ≥75%, ≥90%, or 100% reduction of EASI in four body regions: (1) head and neck, (2) trunk (including genitals), (3) upper limbs, and (4) lower limbs (including buttocks) at each study visit through week 24. Patient response data from the Head and Neck Patient Global Impression of Severity (HN-PGIS) were also analyzed at each study visit for comparison of upadacitinib to dupilumab.
Results
Greater proportions of patients treated with upadacitinib versus dupilumab achieved skin clearance rates of ≥75% (EASI 75) at week 1 and higher clearance rates of ≥90% (EASI 90) or 100% (EASI 100) by week 4 or earlier in all four body regions. This difference was maintained at each visit through week 24 for both EASI 90 and EASI 100. Patient responses on the HN-PGIS indicated that a greater proportion of patients (nominal p value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
- Department of Dermatology, Tufts University School of Medicine, Boston, Massachusetts, USA.
- Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
- Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.
- The Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.
- NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Zitieren
APA
Thyssen, J. P., Rosmarin, D., Costanzo, A., Warren, R., Chu, C. Y., Chovatiya, R., Ladizinski, B., Hu, X., Liu, Y., Calimlim, B., Nduaka, C., Vigna, N., & Armstrong, A. (2024). Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study. Dermatology, 1-9. https://doi.org/10.1159/000542275
Vancouver
Thyssen JP, Rosmarin D, Costanzo A, Warren R, Chu CY, Chovatiya R, et al. Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study. Dermatology. 2024:1-9. doi:10.1159/000542275
BibTeX
@article{Thyssen2024,
author = {Thyssen, Jacob P and Rosmarin, David and Costanzo, Antonio and Warren, Richard and Chu, Chia-Yu and Chovatiya, Raj and Ladizinski, Barry and Hu, Xiaofei and Liu, Yingyi and Calimlim, Brian and Nduaka, Chudi and Vigna, Namita and Armstrong, April},
title = {Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study},
journal = {Dermatology},
year = {2024},
pages = {1--9},
doi = {10.1159/000542275}
}
EUVIMED